159 related articles for article (PubMed ID: 38197078)
1. Predicting therapeutic responses in head and neck squamous cell carcinoma from
Wei M; Zhi J; Li L; Wang W
Transl Cancer Res; 2023 Dec; 12(12):3604-3617. PubMed ID: 38197078
[TBL] [Abstract][Full Text] [Related]
2. Correlate the
Lyu H; Li M; Jiang Z; Liu Z; Wang X
Comput Struct Biotechnol J; 2019; 17():1020-1030. PubMed ID: 31428295
[TBL] [Abstract][Full Text] [Related]
3. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
Zhou G; Liu Z; Myers JN
J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
[TBL] [Abstract][Full Text] [Related]
4. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
5. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
[TBL] [Abstract][Full Text] [Related]
6. Expression levels of miR-34-family microRNAs are associated with TP53 mutation status in head and neck squamous cell carcinoma.
Metheetrairut C; Chotigavanich C; Amornpichetkul K; Keskool P; Ongard S; Metheetrairut C
Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):521-533. PubMed ID: 30515607
[TBL] [Abstract][Full Text] [Related]
7. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
8. HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma.
Chen Y; Yang J; Jin H; Wen W; Xu Y; Zhang X; Wang Y
PeerJ; 2023; 11():e16237. PubMed ID: 37842043
[TBL] [Abstract][Full Text] [Related]
9.
Nasrollahzadeh D; Roshandel G; Delhomme TM; Avogbe PH; Foll M; Saidi F; Poustchi H; Sotoudeh M; Malekzadeh R; Brennan P; Mckay J; Hainaut P; Abedi-Ardekani B
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073316
[TBL] [Abstract][Full Text] [Related]
10. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
Shi C; Liu S; Tian X; Wang X; Gao P
BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
[TBL] [Abstract][Full Text] [Related]
11. Droplet digital polymerase chain reaction for detection and quantification of cell-free DNA TP53 target somatic mutations in oral cancer.
Lin LH; Cheng HW; Liu CJ
Cancer Biomark; 2022; 33(1):29-41. PubMed ID: 34366328
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next-generation sequencing panel: A preliminary study.
Rapado-González Ó; Brea-Iglesias J; Rodríguez-Casanova A; Bao-Caamano A; López-Cedrún JL; Triana-Martínez G; Díaz-Peña R; Santos MA; López-López R; Muinelo-Romay L; Martínez-Fernández M; Díaz-Lagares Á; Suárez-Cunqueiro MM
Cancer Med; 2023 Mar; 12(6):6615-6622. PubMed ID: 36420687
[TBL] [Abstract][Full Text] [Related]
13. Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer.
Park YR; Kim YM; Lee SW; Lee HY; Lee GE; Lee JE; Kim YT
Obstet Gynecol Sci; 2018 May; 61(3):328-336. PubMed ID: 29780774
[TBL] [Abstract][Full Text] [Related]
14. High-risk TP53 mutations predict poor primary treatment response of patients with head and neck squamous cell carcinoma.
Caponio VCA; Zhurakivska K; Mascitti M; Togni L; Spirito F; Cirillo N; Lo Muzio L; Troiano G
Oral Dis; 2024 May; 30(4):2018-2026. PubMed ID: 37501500
[TBL] [Abstract][Full Text] [Related]
15. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
El Baroudi M; Machiels JP; Schmitz S
Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
van Harten AM; Poell JB; Buijze M; Brink A; Wells SI; René Leemans C; Wolthuis RMF; Brakenhoff RH
Oral Oncol; 2019 Nov; 98():53-61. PubMed ID: 31541927
[TBL] [Abstract][Full Text] [Related]
17. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
[TBL] [Abstract][Full Text] [Related]
18. Subtyping of head and neck squamous cell cancers based on immune signatures.
Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
[TBL] [Abstract][Full Text] [Related]
19. The implications of gene mutations in salivary DNA for noninvasive diagnosis of head and neck cancer with a focus on oral cancer.
Yang X; Song H; Ji T; Du G; Liu W
Oral Oncol; 2022 Jul; 130():105924. PubMed ID: 35594773
[TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
